Neuropathic Pain Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies – WEX Pharmaceuticals Inc., Lexicon Pharmaceuticals Inc., Bayer

November 09 19:05 2022
Neuropathic Pain Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies - WEX Pharmaceuticals Inc., Lexicon Pharmaceuticals Inc., Bayer
The Neuropathic Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neuropathic Pain pipeline products will significantly revolutionize the Neuropathic Pain market dynamics.

DelveInsight’s “Neuropathic Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Neuropathic Pain, historical and forecasted epidemiology as well as the Neuropathic Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Neuropathic Pain market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 


To Know in detail about the Neuropathic Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neuropathic Pain Market Insights 


Neuropathic Pain Overview

According to the International Association for the Study of Pain (IASP), neuropathic pain is defined as “pain initiated or caused by a primary lesion or dysfunction in the nervous system. Chronic neuropathic pain is common and may be related to an underlying health condition such as cancer or diabetic neuropathy, or it could be related to treatments such as chemotherapy.


Some of the key facts of the Neuropathic Pain Market Report: 

  • The Neuropathic Pain market size is anticipated to grow with a significant CAGR during the study period (2019-2032) 
  • According to Bouhassira D, the prevalence of neuropathic pain in the general population may be as high as 7 to 8%, accounting for 20 to 25% of individuals with chronic pain 
  • In a study by Pottathil S, the incidence of chronic neuropathic pain is 10–14% in the United Kingdom, 9.8–12.4% in the United States, and 7–10% worldwide 
  • Key Neuropathic Pain Companies: WEX Pharmaceuticals Inc., Lexicon Pharmaceuticals Inc., Bayer, and others
  • Key Neuropathic Pain Therapies: Halneuron, LX9211, BAY2395840, and others 
  • The Neuropathic Pain epidemiology based on gender analyzed that Neuropathic Pain disease affects females more as compared to males 


Get a Free sample for the Neuropathic Pain Market Report


Key benefits of the Neuropathic Pain Market report:

  1. Neuropathic Pain market report covers a descriptive overview and comprehensive insight of the Neuropathic Pain Epidemiology and Neuropathic Pain market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Neuropathic Pain market report provides insights on the current and emerging therapies.
  3. Neuropathic Pain market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Neuropathic Pain market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Neuropathic Pain market.


Download the report to understand which factors are driving Neuropathic Pain epidemiology trends @ Neuropathic Pain Epidemiological Insights


Neuropathic Pain Market  

The dynamics of the Neuropathic Pain market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  

“The approval of novel therapies for the treatment of neuropathic pain has led to a major uptick in the DNP drugs market, In January 2022, US FDA approved the Senza Omnia spinal cord stimulation (SCS) system for the treatment of chronic neuropathic pain. Another drug, Tarlige (Mirogabalin besylate), was approved by PMDA Japan for NP, in 2022.” 


Neuropathic Pain Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.


Neuropathic Pain Epidemiology Segmentation:

The Neuropathic Pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Neuropathic Pain
  • Prevalent Cases of Neuropathic Pain by severity
  • Gender-specific Prevalence of Neuropathic Pain
  • Diagnosed Cases of Episodic and Chronic Neuropathic Pain


Neuropathic Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neuropathic Pain market or expected to get launched during the study period. The analysis covers Neuropathic Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Neuropathic Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.


Discover more about therapies set to grab major Neuropathic Pain market share @ Neuropathic Pain market forecast 


Neuropathic Pain Therapies and Key Companies

  • Halneuron: WEX Pharmaceuticals Inc.
  • LX9211: Lexicon Pharmaceuticals Inc.
  • BAY2395840: Bayer


Neuropathic Pain Market Drivers

  • The major strength of the Neuropathic Pain (NP) market is the potential emerging therapies 
  • Growing research and developmental activities about this indication


Scope of the Neuropathic Pain Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Neuropathic Pain Companies: WEX Pharmaceuticals Inc., Lexicon Pharmaceuticals Inc., Bayer, and others
  • Key Neuropathic Pain Therapies: Halneuron, LX9211, BAY2395840, and others
  • Neuropathic Pain Therapeutic Assessment: Neuropathic Pain current marketed and Neuropathic Pain emerging therapies
  • Neuropathic Pain Market Dynamics:  Neuropathic Pain market drivers and Neuropathic Pain market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Neuropathic Pain Unmet Needs, KOL’s views, Analyst’s views, Neuropathic Pain Market Access and Reimbursement 


Neuropathic Pain Market Unmet Needs

  • Challenges in diagnoses
  • Development of novel therapies
  • Limitations in gene therapy
  • Poor disease understanding
  • Clinical biomarkers


Table of Contents 

1. Neuropathic Pain Market Report Introduction

2. Executive Summary for Neuropathic Pain

3. SWOT analysis of Neuropathic Pain

4. Neuropathic Pain Patient Share (%) Overview at a Glance

5. Neuropathic Pain Market Overview at a Glance

6. Neuropathic Pain Disease Background and Overview

7. Neuropathic Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Neuropathic Pain 

9. Neuropathic Pain Current Treatment and Medical Practices

10. Neuropathic Pain Unmet Needs

11. Neuropathic Pain Emerging Therapies

12. Neuropathic Pain Market Outlook

13. Country-Wise Neuropathic Pain Market Analysis (2019–2032)

14. Neuropathic Pain Market Access and Reimbursement of Therapies

15. Neuropathic Pain Market Drivers

16. Neuropathic Pain Market Barriers

17.  Neuropathic Pain Appendix

18. Neuropathic Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight


To know more about Neuropathic Pain treatment, visit @ Neuropathic Pain Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States